Physician profile
Saif Abdel Raouf A Bushnaq
NPI 1124435987
$5,890.05
in general payments reported to CMS, 2019-2025
13 companies · $2,498 in 2025
The $2,498 reported for 2025 was more than what 82% of Vascular Neurology providers received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.92 · 2021: $1,284 · 2022: $593 · 2023: $623 · 2024: $870 · 2025: $2,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,990.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $2,580.98 | 2021-2025 | Penumbra System, Red 72, Pod |
| Imperative Care, INC | $748.27 | 2021-2025 | Zoom 88-T Large Distal Platform, Zoom 7x Catheter, Zoom Catheter |
| Stryker Corporation | $653.32 | 2021-2025 | Surpass Evolve, Target, Ivas |
| Route 92 Medical, INC. | $641.96 | 2025 | |
| Depuy Synthes Sales INC. | $467.82 | 2021-2022 | |
| Microvention, INC. | $297.35 | 2021-2022 | |
| Medtronic, INC. | $265.91 | 2021-2025 | Pipeline, Solitaire X, Rist |
| Novartis Pharmaceuticals Corporation | $116.72 | 2024 | |
| Qapel Medical INC | $54.84 | 2023-2025 | |
| Argenx US, INC. | $26.44 | 2025 | Vyvgart Hytrulo |
| Livanova USA, INC. | $22.92 | 2020 | |
| Biogen, INC. | $13.52 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saif Bushnaq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.